Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
2013 4
2014 2
2015 1
2017 3
2018 2
2019 1
2021 2
2022 4
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Results by year

Filters applied: . Clear all
Page 1
Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients.
Gottlieb RL, Vaca CE, Paredes R, Mera J, Webb BJ, Perez G, Oguchi G, Ryan P, Nielsen BU, Brown M, Hidalgo A, Sachdeva Y, Mittal S, Osiyemi O, Skarbinski J, Juneja K, Hyland RH, Osinusi A, Chen S, Camus G, Abdelghany M, Davies S, Behenna-Renton N, Duff F, Marty FM, Katz MJ, Ginde AA, Brown SM, Schiffer JT, Hill JA; GS-US-540-9012 (PINETREE) Investigators. Gottlieb RL, et al. N Engl J Med. 2022 Jan 27;386(4):305-315. doi: 10.1056/NEJMoa2116846. Epub 2021 Dec 22. N Engl J Med. 2022. PMID: 34937145 Free PMC article. Clinical Trial.
Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma.
Perry JR, Laperriere N, O'Callaghan CJ, Brandes AA, Menten J, Phillips C, Fay M, Nishikawa R, Cairncross JG, Roa W, Osoba D, Rossiter JP, Sahgal A, Hirte H, Laigle-Donadey F, Franceschi E, Chinot O, Golfinopoulos V, Fariselli L, Wick A, Feuvret L, Back M, Tills M, Winch C, Baumert BG, Wick W, Ding K, Mason WP; Trial Investigators. Perry JR, et al. N Engl J Med. 2017 Mar 16;376(11):1027-1037. doi: 10.1056/NEJMoa1611977. N Engl J Med. 2017. PMID: 28296618 Free article. Clinical Trial.
Brain Growth Charts for Quantitative Analysis of Pediatric Clinical Brain MRI Scans with Limited Imaging Pathology.
Schabdach JM, Schmitt JE, Sotardi S, Vossough A, Andronikou S, Roberts TP, Huang H, Padmanabhan V, Ortiz-Rosa A, Gardner M, Covitz S, Bedford SA, Mandal AS, Chaiyachati BH, White SR, Bullmore E, Bethlehem RAI, Shinohara RT, Billot B, Iglesias JE, Ghosh S, Gur RE, Satterthwaite TD, Roalf D, Seidlitz J, Alexander-Bloch A; Lifespan Brain Chart Consortium. Schabdach JM, et al. Radiology. 2023 Oct;309(1):e230096. doi: 10.1148/radiol.230096. Radiology. 2023. PMID: 37906015
RSNA, 2023 Supplemental material is available for this article. See also the editorial by Ertl-Wagner and Pai in this issue....
RSNA, 2023 Supplemental material is available for this article. See also the editorial by Ertl-Wagner and Pai in this issue....
Sirtuin 5 promotes arterial thrombosis by blunting the fibrinolytic system.
Liberale L, Akhmedov A, Vlachogiannis NI, Bonetti NR, Nageswaran V, Miranda MX, Puspitasari YM, Schwarz L, Costantino S, Paneni F, Beer JH, Ruschitzka F, Montecucco F, Lüscher TF, Stamatelopoulos K, Stellos K, Camici GG. Liberale L, et al. Cardiovasc Res. 2021 Aug 29;117(10):2275-2288. doi: 10.1093/cvr/cvaa268. Cardiovasc Res. 2021. PMID: 32931562
Accordingly, Sirt5-/- mice showed reduced plasma and vascular expression of the fibrinolysis inhibitor plasminogen activator inhibitor (PAI)-1. In HAECs, SIRT5-silencing inhibited PAI-1 gene and protein expression in response to TNF-alpha. This effect was mediated b …
Accordingly, Sirt5-/- mice showed reduced plasma and vascular expression of the fibrinolysis inhibitor plasminogen activator inhibitor (P …
A randomized double-blind placebo-controlled trial of an inhibitor of plasminogen activator inhibitor-1 (TM5614) in mild to moderate COVID-19.
Hirai T, Asano K, Ito I, Miyazaki Y, Sugiura H, Agirbasli M, Kobayashi S, Kobayashi M, Shimada D, Natsume I, Kawasaki T, Ohba T, Tajiri S, Sakamaki F, Mineshita M, Takihara T, Sekiya K, Tomii K, Tomioka H, Kita H, Nishizaka Y, Fukui M, Miyata T, Harigae H. Hirai T, et al. Sci Rep. 2024 Jan 2;14(1):165. doi: 10.1038/s41598-023-50445-1. Sci Rep. 2024. PMID: 38168544 Free PMC article. Clinical Trial.
An inhibitor of plasminogen activator inhibitor (PAI)-1, TM5614, inhibited thrombosis, inflammation, and fibrosis in several experimental mouse models. ...The total oxygenation scale from Day 1 to Day 14 as the primary endpoint was 1.5 in the TM5614 group vs 4.0 in the pla …
An inhibitor of plasminogen activator inhibitor (PAI)-1, TM5614, inhibited thrombosis, inflammation, and fibrosis in several experime …
The procoagulant molecule plasminogen activator inhibitor-1 is associated with injury severity and shock in patients with and without traumatic brain injury.
Condron M, Rowell S, Dewey E, Anderson T, Lealiiee L, Farrell D, Hinson H. Condron M, et al. J Trauma Acute Care Surg. 2018 Nov;85(5):888-893. doi: 10.1097/TA.0000000000002040. J Trauma Acute Care Surg. 2018. PMID: 30086072 Free PMC article.
We hypothesized that elevated PAI-1 levels would be associated with increased Injury Severity Score (ISS) in injured patients with and without traumatic brain injury and that PAI-1 levels would vary with injury type. ...After adjusting for age, sex, hypotension, and …
We hypothesized that elevated PAI-1 levels would be associated with increased Injury Severity Score (ISS) in injured patients with an …
Deep molecular response in patients with chronic phase chronic myeloid leukemia treated with the plasminogen activator inhibitor-1 inhibitor TM5614 combined with a tyrosine kinase inhibitor.
Takahashi N, Kameoka Y, Onizuka M, Onishi Y, Takahashi F, Dan T, Miyata T, Ando K, Harigae H. Takahashi N, et al. Cancer Med. 2023 Feb;12(4):4250-4258. doi: 10.1002/cam4.5292. Epub 2022 Sep 23. Cancer Med. 2023. PMID: 36151699 Free PMC article.
BACKGROUND: We recently showed that pharmacological inhibition of plasminogen activator inhibitor-1 (PAI-1) activity, based on TM5614, increases cell motility and induces the detachment of hematopoietic stem cells from their niches. In this TM5614 phase II clinical trial, …
BACKGROUND: We recently showed that pharmacological inhibition of plasminogen activator inhibitor-1 (PAI-1) activity, based on TM5614 …
Level of circulating concentrations of progesterone during ovulatory follicle development affects timing of pregnancy loss in lactating dairy cows.
Martins JPN, Wang D, Mu N, Rossi GF, Martini AP, Martins VR, Pursley JR. Martins JPN, et al. J Dairy Sci. 2018 Nov;101(11):10505-10525. doi: 10.3168/jds.2018-14410. Epub 2018 Sep 7. J Dairy Sci. 2018. PMID: 30197145 Free article.
Progesterone (P4) was manipulated to reach high (H) or low (L) serum concentrations during the pre-dominance phase (d 0 to 4 of the wave) and dominance phase (d 5 to 7 of the wave) of a second follicular wave ovulatory follicle, creating 4 treatments: H/H, H/ …
Progesterone (P4) was manipulated to reach high (H) or low (L) serum concentrations during the pre-dominance phase (d 0 to 4 of the wave) an …
22 results